Infliximab for Immune Checkpoint Inhibitor Associated AKI

This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed of renal recovery from immune checkpoint inhibitor-associated AKI.

NCT Number	NCT07683975
Lead Sponsor	Massachusetts General Hospital Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions	Acute Kidney Injury, Acute Interstitial Nephritis
Enrollment	44 participants
Start Date	2026-07-16
Primary Completion	2029-01-15 (estimated)
Study Completion	2029-07-16 (estimated)
Updated on ClinicalTrials.gov	2026-07-06